These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23593291)

  • 1. Knockdown of PPAR δ gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model.
    Yang L; Zhou J; Ma Q; Wang C; Chen K; Meng W; Yu Y; Zhou Z; Sun X
    PLoS One; 2013; 8(4):e60715. PubMed ID: 23593291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
    Choi IK; Kim YH; Kim JS; Seo JH
    Invest New Drugs; 2008 Jun; 26(3):283-8. PubMed ID: 18161004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells.
    Yang L; Olsson B; Pfeifer D; Jönsson JI; Zhou ZG; Jiang X; Fredriksson BA; Zhang H; Sun XF
    Oncogene; 2010 Jan; 29(4):516-26. PubMed ID: 19935699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts].
    Zhou CF; Ji J; Yuan F; Yu YY; Liu BY; Zhang J; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):180-4. PubMed ID: 22368029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis.
    Zuo X; Peng Z; Moussalli MJ; Morris JS; Broaddus RR; Fischer SM; Shureiqi I
    J Natl Cancer Inst; 2009 May; 101(10):762-7. PubMed ID: 19436036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.
    Forootan FS; Forootan SS; Gou X; Yang J; Liu B; Chen D; Al Fayi MS; Al-Jameel W; Rudland PS; Hussain SA; Ke Y
    Oncotarget; 2016 Feb; 7(8):9322-39. PubMed ID: 26814431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate.
    Paudyal B; Paudyal P; Shah D; Tominaga H; Tsushima Y; Endo K
    J Biomed Sci; 2014 Apr; 21(1):35. PubMed ID: 24780003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of transcription by the peroxisome proliferator-activated receptor delta--binding RNA aptamer in colon cancer cells.
    Kwak H; Hwang I; Kim JH; Kim MY; Yang JS; Jeong S
    Mol Cancer Ther; 2009 Sep; 8(9):2664-73. PubMed ID: 19723884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
    Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition in colon cancer.
    Qiao L; Dai Y; Gu Q; Chan KW; Zou B; Ma J; Wang J; Lan HY; Wong BC
    Mol Cancer Ther; 2008 Jul; 7(7):2203-11. PubMed ID: 18645029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells.
    Röhrl C; Kaindl U; Koneczny I; Hudec X; Baron DM; König JS; Marian B
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):29-39. PubMed ID: 20221637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihomo-γ-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
    Xu Y; Yang X; Gao D; Yang L; Miskimins K; Qian SY
    BMC Cancer; 2018 Dec; 18(1):1268. PubMed ID: 30567534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
    Kaliberova LN; Kusmartsev SA; Krendelchtchikova V; Stockard CR; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Mol Cancer Ther; 2009 Nov; 8(11):3130-9. PubMed ID: 19887544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism.
    Zhao M; Yu Z; Li Z; Tang J; Lai X; Liu L
    Oncol Rep; 2017 Jan; 37(1):601-607. PubMed ID: 27840995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARδ deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells.
    Jeong E; Koo JE; Yeon SH; Kwak MK; Hwang DH; Lee JY
    Mol Carcinog; 2014 Nov; 53(11):926-37. PubMed ID: 24610641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.